How tirzepatide's GIP action sets it apart from other weight-loss medicines

Step 1, what GIP is and why it matters

GIP stands for glucose-dependent insulinotropic polypeptide, a hormone secreted by specialised K-cells lining the upper small intestine within minutes of eating. For decades it was studied mainly in the context of insulin release, GIP signals the pancreas to produce insulin in proportion to the glucose arriving from a meal. That part of its job is fairly well understood. What researchers have found more recently is that GIP receptors exist in a much broader range of tissues: fat cells, the brain, bone, and possibly muscle. When those receptors are activated, GIP appears to support fat storage at physiological doses, but at the higher, sustained activation levels produced by a GIP receptor agonist, animal and human studies suggest the opposite effect, reduced fat accumulation and improved fat metabolism. If you want a closer look at the specific mechanism, the page on what GIP stands for in tirzepatide goes into the receptor pharmacology in more detail. The short version: GIP is not a passive bystander in weight regulation; it appears to amplify or modulate the appetite signals sent through the GLP-1 pathway, and that interaction is central to how tirzepatide was designed, as you can explore further on the page covering how GIP works in tirzepatide.

Step 2, how GLP-1 fits in, and what changes when both receptors fire together

GLP-1 is released from L-cells lower in the gut, a little later in the digestive process. Its effects are better-characterised in the public conversation around weight-loss medicines because GLP-1 receptor agonists have been used clinically for longer. GLP-1 slows the rate at which the stomach empties, signals fullness to the hypothalamus, and (in people with type 2 diabetes) reduces excess glucagon. Semaglutide (Wegovy) activates the GLP-1 receptor only. Tirzepatide, sold in the UK as Mounjaro, adds the GIP receptor on top. In clinical practice, the combination appears to produce appetite suppression that is meaningfully greater than GLP-1 activation alone. The SURMOUNT-5 head-to-head trial, published in the New England Journal of Medicine in 2025, compared tirzepatide directly with semaglutide 2.4 mg in adults with obesity and found greater average weight reduction with tirzepatide. The mechanism behind that difference is not fully established (researchers continue to study whether GIP's role is additive, synergistic, or partially explained by downstream effects) but the clinical signal is clear. You can read about the dual-agonist classification specifically on the page covering tirzepatide as a GIP agonist.

Step 3, what this means for treatment in practice

Understanding the GIP component matters for a practical reason: it partly explains why tirzepatide's side-effect profile and dose-escalation schedule look the way they do. Treatment begins at 2.5 mg, a starter dose designed to let the body adjust to both receptors being activated at once, reducing the likelihood of early nausea. The prescriber then reviews progress and, where appropriate, moves the dose upward through the licensed schedule over successive weeks. Tolerability varies by person; some find the GI effects (nausea, loose stools, constipation, indigestion) most noticeable after dose changes, then settling. The tirzepatide overview covers the full dose range and what to expect at each stage. One practical detail worth noting: Mounjaro arrives as a pre-filled KwikPen, each pen containing four weekly doses, delivered in plain packaging by DPD with tracking, the pen goes straight in the fridge door on arrival. On the question of cost, the Mounjaro price page sets out what private treatment typically includes and what the NHS route involves. The NHS page on tirzepatide covers licensed uses, common side effects and storage in full. NICE's appraisal (TA1026), which recommends tirzepatide for adults with a BMI of 35 or above and at least one weight-related condition, sets out both the evidence base and the NHS eligibility criteria in detail.

Step 4 (who this applies to and the clinical assessment step

Tirzepatide is licensed in the UK for adults with a BMI of 30 or above, or 27 or above where at least one weight-related condition is present) conditions such as high blood pressure, type 2 diabetes, high cholesterol, or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. A BMI alone does not determine suitability; the prescriber considers the complete clinical picture, including any medicines you take, medical history, and whether the timing is appropriate (it is not recommended during pregnancy, breastfeeding, or when actively trying to conceive). The weight-loss treatment overview explains how different options compare. For a fuller account of how the GIP and GLP-1 pathways interact in tirzepatide's mechanism, the page on tirzepatide's GLP-1 and GIP pathways covers the science alongside the clinical evidence. Our clinical team reviews every consultation personally, if you have questions about whether tirzepatide is appropriate for your situation, speaking to our prescribers is the right next step.